{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:35:36Z","timestamp":1772890536012,"version":"3.50.1"},"reference-count":116,"publisher":"Elsevier","isbn-type":[{"value":"9780444642776","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmch.2019.01.001","type":"book-chapter","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T13:52:13Z","timestamp":1551448333000},"page":"157-187","source":"Crossref","is-referenced-by-count":23,"title":["Natural product drug delivery: A special challenge?"],"prefix":"10.1016","author":[{"given":"Neil J.","family":"Press","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drudis.2015.01.009","article-title":"An analysis of FDA-approved drugs: natural products and their derivatives","volume":"21","author":"Patridge","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0015","series-title":"Dictionary of natural products","author":"Taylor & Francis Group","year":"2018"},{"issue":"7","key":"10.1016\/bs.pmch.2019.01.001_bb0020","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J Chem Inf Model"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0025","doi-asserted-by":"crossref","first-page":"36\/1","DOI":"10.1186\/s13321-017-0225-z","article-title":"An algorithm to identify functional groups in organic molecules","volume":"9","author":"Ertl","year":"2017","journal-title":"J Cheminformatics"},{"issue":"6","key":"10.1016\/bs.pmch.2019.01.001_bb0030","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1021\/acs.jnatprod.5b00255","article-title":"Analysis of physicochemical properties for drugs of natural origin","volume":"78","author":"Camp","year":"2015","journal-title":"J Nat Prod"},{"issue":"2\u20133","key":"10.1016\/bs.pmch.2019.01.001_bb0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF03190191","article-title":"Transport of peptide and protein drugs across biological membranes","volume":"15","author":"Verhoef","year":"1990","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0045","first-page":"1867","article-title":"The discovery and development of cyclosporine (Sandimmune)","volume":"23","author":"Borel","year":"1991","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2125.1991.tb05540.x","article-title":"Cyclosporin metabolism by the gastrointestinal mucosa","volume":"31","author":"Tjia","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/03639040601155665","article-title":"Cyclosporine A: a review of current oral and intravenous delivery systems","volume":"33","author":"Beauchesne","year":"2007","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0065","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.ftd.0000211804.89440.74","article-title":"Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers","volume":"28","author":"Kees","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2710.1990.tb00386.x","article-title":"Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags","volume":"15","author":"Wood","year":"1990","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0080","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/10611869408996815","article-title":"Sterically stabilized liposomes: physical and biological properties","volume":"2","author":"Woodle","year":"1994","journal-title":"J Drug Target"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2019.01.001_bb0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(97)00136-1","article-title":"Controlling liposome blood clearance by surface-grafted polymers","volume":"32","author":"Woodle","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0090","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Lee LW reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0936-6555(05)80269-9","article-title":"Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS","volume":"6","author":"James","year":"1994","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000327767","article-title":"Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment","volume":"4","author":"Farr","year":"2011","journal-title":"Case Rep Oncol"},{"issue":"1\u20133","key":"10.1016\/bs.pmch.2019.01.001_bb0105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0168-3659(01)00344-3","article-title":"Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC)","volume":"74","author":"Rudge","year":"2001","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1148\/radiol.2301021493","article-title":"Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging\/conventional angiography suite--initial experience with four patients","volume":"230","author":"Wilson","year":"2004","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0115","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10856-009-3803-4","article-title":"Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model","volume":"21","author":"Baltes","year":"2010","journal-title":"J Mater Sci Mater Med"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082331","article-title":"Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101)","volume":"9","author":"Gaillard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0125","series-title":"Nanostructured biomaterials for overcoming biological barriers","first-page":"591","article-title":"A clinically relevant case study: the development of Livatag for the treatment of advanced hepatocellular carcinoma","volume":"22","author":"Soma","year":"2012"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.2042-7158.1979.tb13510.x","article-title":"Polycyanoacrylate nanocapsules as potential lysosomotropic carriers\u2014preparation, morphological and sorptive properties","volume":"31","author":"Couvreur","year":"1979","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0135","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF02897257","article-title":"Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. Administration in reticulosarcoma M 5076 metastasis-bearing mice","volume":"26","author":"Chiannilkulchai","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0006-2952(92)90443-M","article-title":"Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance","volume":"44","author":"Cuvier","year":"1992","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0145","first-page":"1195","article-title":"Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1","volume":"23","author":"Aouali","year":"2003","journal-title":"Int J Oncol"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0150","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/nbt.2437","article-title":"What's fueling the biotech engine\u20142011 to 2012","volume":"30","author":"Aggarwal","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"Suppl. 3","key":"10.1016\/bs.pmch.2019.01.001_bb0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2337\/diacare.16.3.133","article-title":"Research, development, production, and safety of biosynthetic human insulin","volume":"16","author":"Chance","year":"1993","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1467-7652.2005.00159.x","article-title":"Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds","volume":"4","author":"Nykiforuk","year":"2006","journal-title":"Plant Biotechnol J"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0165","first-page":"73","article-title":"Insulin formulations--a review","volume":"5","author":"Gualandi-Signorini","year":"2001","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2337\/diacare.3.5.623","article-title":"Intermediate-acting insulin preparations: NPH and lente","volume":"3","author":"Deckert","year":"1980","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0175","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2337\/diab.43.3.396","article-title":"[Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin","volume":"43","author":"Howey","year":"1994","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2005.05.022","article-title":"An enteric-coated dry emulsion formulation for oral insulin delivery","volume":"107","author":"Toorisaka","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0185","series-title":"Oral delivery of insulin","first-page":"113","article-title":"3\u2014Oral insulin delivery\u2014challenges and strategies","author":"Sonia","year":"2014"},{"issue":"7537","key":"10.1016\/bs.pmch.2019.01.001_bb0190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bmj.332.7537.321","article-title":"Inhaled insulin is approved in Europe and United States","volume":"332","author":"Lenzer","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coph.2017.07.015","article-title":"Inhalation delivery of complex drugs-the next steps","volume":"36","author":"de Kruijf","year":"2017","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0200","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ddr.20238","article-title":"The science behind Exubera","volume":"69","author":"Schachner","year":"2008","journal-title":"Drug Dev Res"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0205","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/193229680800200325","article-title":"The failure of exubera: are we beating a dead horse?","volume":"2","author":"Lutz","year":"2008","journal-title":"J Diabetes Sci Technol"},{"issue":"14","key":"10.1016\/bs.pmch.2019.01.001_bb0210","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2146\/ajhp140540","article-title":"A second-generation inhaled insulin for diabetes mellitus","volume":"72","author":"Ledet","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0215","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2018\/4568903","article-title":"Rethinking the viability and utility of inhaled insulin in clinical practice","volume":"2018","author":"Heinemann","year":"2018","journal-title":"J Diabetes Res"},{"issue":"11","key":"10.1016\/bs.pmch.2019.01.001_bb0220","first-page":"735","article-title":"Afrezza (insulin human) inhalation powder: a new inhaled insulin for the management of Type-1 or Type-2 diabetes mellitus","volume":"40","author":"Goldberg","year":"2015","journal-title":"P T"},{"issue":"3\u20134","key":"10.1016\/bs.pmch.2019.01.001_bb0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drudis.2006.12.008","article-title":"Targeting mammalian target of rapamycin (mTOR) for health and diseases","volume":"12","author":"Tsang","year":"2007","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0235","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0928-0987(02)00251-8","article-title":"Nano-sizing: a formulation approach for poorly-water-soluble compounds","volume":"18","author":"Merisko-Liversidge","year":"2003","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0240","first-page":"135","article-title":"Nanoparticle-based therapeutics in humans: a survey","volume":"5","author":"Bawa","year":"2008","journal-title":"Nanotechnol Law Bus"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0245","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00003495-200666040-00009","article-title":"Everolimus: a review of its use in renal and cardiac transplantation","volume":"66","author":"Dunn","year":"2006","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0250","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0041-1345(98)00587-9","article-title":"Chemical modification of rapamycin: the discovery of SDZ RAD","volume":"30","author":"Sedrani","year":"1998","journal-title":"Transplant Proc"},{"issue":"10","key":"10.1016\/bs.pmch.2019.01.001_bb0255","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1021\/js980403l","article-title":"Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs","volume":"88","author":"Serajuddin","year":"1999","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0260","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.apsb.2013.11.001","article-title":"Fundamental aspects of solid dispersion technology for poorly soluble drugs","volume":"4","author":"Huang","year":"2014","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"10.1016\/bs.pmch.2019.01.001_bb0265","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrd2382","article-title":"Temsirolimus","volume":"6","author":"Rini","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/11586010-000000000-00000","article-title":"Ridaforolimus","volume":"10","author":"Anon","year":"2010","journal-title":"Drugs R&D"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0275","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.14555","article-title":"Pharmacokinetics of oral deforolimus (AP23573, MK-8669)","volume":"26","author":"Fetterly","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0280","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1358\/dot.1998.34.5.485245","article-title":"Pharmacology of immunosuppressive drugs","volume":"34","author":"Olyaei","year":"1998","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/13543784.5.2.225","article-title":"Recent developments with immunosuppressant macrolides: tacrolimus and sirolimus","volume":"5","author":"Wallemacq","year":"1996","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/bs.pmch.2019.01.001_bb0290","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0295","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/2230-973X.106981","article-title":"Formulation strategies for drug delivery of tacrolimus: an overview","volume":"2","author":"Patel","year":"2012","journal-title":"Int J Pharm Investig"},{"issue":"11","key":"10.1016\/bs.pmch.2019.01.001_bb0300","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1124\/dmd.117.076737","article-title":"Wuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent for renal transplant recipients who are CYP3A5 expressers: a two-phase prospective Study","volume":"45","author":"Li","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0305","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijpharm.2010.01.025","article-title":"Mechanistic understanding of the different effects of Wuzhi tablet (Schisandrasphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of tacrolimus (FK506)","volume":"389","author":"Qin","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0310","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2125.2007.02922.x","article-title":"Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers","volume":"64","author":"Xin","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/bs.pmch.2019.01.001_bb0315","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2165\/11593890-000000000-00000","article-title":"Once- versus twice-daily tacrolimus: are the formulations truly equivalent?","volume":"71","author":"Barraclough","year":"2011","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0320","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jphp.12515","article-title":"Preparation of extended release solid dispersion formulations of tacrolimus using ethylcellulose and hydroxypropylmethylcellulose by solvent evaporation method","volume":"68","author":"Tsunashima","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0325","first-page":"226","article-title":"The antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. Influenzae","volume":"10","author":"Fleming","year":"1929","journal-title":"Br J Exp Pathol"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0330","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.spid.2004.02.001","article-title":"Penicillin: its discovery and early development","volume":"15","author":"Ligon","year":"2004","journal-title":"Semin Pediatr Infect Dis"},{"issue":"8","key":"10.1016\/bs.pmch.2019.01.001_bb0335","first-page":"681","article-title":"Penicillins\u2014new insights into their mechanisms of activity and clinical use","volume":"58","author":"Neu","year":"1982","journal-title":"Bull N Y Acad Med"},{"issue":"Suppl. 6","key":"10.1016\/bs.pmch.2019.01.001_bb0340","first-page":"vi13","article-title":"European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe (1997\u20132009)","volume":"66","author":"Versporten","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0345","series-title":"\u03b2-Lactam antibiotics","author":"Hubschwerlen","year":"2006"},{"issue":"1","key":"10.1016\/bs.pmch.2019.01.001_bb0350","first-page":"15","article-title":"The second international standard for penicillin","volume":"9","author":"Humphrey","year":"1953","journal-title":"Bull World Health Organ"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0355","series-title":"Goodman & Gilman's: the pharmacological basis of therapeutics, 12e","article-title":"Penicillins, cephalosporins, and other \u03b2-lactam antibiotics","author":"Petri","year":"2011"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0360","first-page":"609","article-title":"\u03b2-Lactam antibiotics: penicillins and cephalosporins","volume":"vol 2","author":"Newall","year":"1990"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0365","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1054-3589(08)60458-5","article-title":"Semisynthetic penicillins","volume":"11","author":"Rolinson","year":"1973","journal-title":"Adv Pharmacol Chemother"},{"issue":"Pt. 1","key":"10.1016\/bs.pmch.2019.01.001_bb0370","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/jmm.0.46124-0","article-title":"Antimicrobial activities of silver dressings: an in vitro comparison","volume":"55","author":"Ip","year":"2006","journal-title":"J Med Microbiol"},{"issue":"22","key":"10.1016\/bs.pmch.2019.01.001_bb0375","doi-asserted-by":"crossref","first-page":"225103","DOI":"10.1088\/0957-4484\/18\/22\/225103","article-title":"Characterization of enhanced antibacterial effects of novel silver nanoparticles","volume":"18","author":"Shrivastava","year":"2007","journal-title":"Nanotechnology"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0380","first-page":"1415","article-title":"Chemically fabricated silver nanoparticles enhances the activity of antibiotics against selected human bacterial pathogens","volume":"3","author":"Thangapandiyan","year":"2012","journal-title":"Int J Pharm Sci Res"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0385","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15407\/biotech6.02.034","article-title":"Silver nanoparticles as penicillin action enhancers","volume":"6","author":"Vasylchenko","year":"2013","journal-title":"Biotechnologia Acta"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0390","series-title":"Antimicrobial agents","first-page":"407","article-title":"Silver nanoparticles: real antibacterial bullets","author":"Thirumurugan","year":"2012"},{"issue":"10","key":"10.1016\/bs.pmch.2019.01.001_bb0395","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1517\/17425247.2010.514604","article-title":"Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery","volume":"7","author":"Duceppe","year":"2010","journal-title":"Expert Opin Drug Deliv"},{"issue":"9","key":"10.1016\/bs.pmch.2019.01.001_bb0400","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1023\/A:1011929016601","article-title":"Chitosan and its use as a pharmaceutical excipient","volume":"15","author":"Ilium","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0405","first-page":"1352","article-title":"Chitosan nanoparticles as a sustained delivery of penicillin G prepared by ionic gelation technique","volume":"8","author":"Safhi","year":"2014","journal-title":"J Pharm Res"},{"issue":"12","key":"10.1016\/bs.pmch.2019.01.001_bb0410","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/j.bmcl.2007.03.077","article-title":"Lim DV penicillin-bound polyacrylate nanoparticles: restoring the activity of beta-lactam antibiotics against MRSA","volume":"17","author":"Turos","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/bs.pmch.2019.01.001_bb0415","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1039\/b111551k","article-title":"Morphine, the proteus of organic molecules","volume":"2002","author":"Blakemore","year":"2002","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0420","series-title":"Paracelsus in the light of four hundred years, march of medicine","author":"Sigerest","year":"1941"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0425","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00003088-199835030-00002","article-title":"Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine","volume":"35","author":"Gourlay","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0430","series-title":"Polymeric materials in drug delivery","author":"Gu","year":"2014"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0435","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1002\/1097-0142(19890601)63:11<2348::AID-CNCR2820631146>3.0.CO;2-V","article-title":"The United States experience with oral controlled-release morphine (MS Contin tablets). Parts I and II. Review of nine dose titration sudies and clinical phramcology of 15-mg, 60-mg and 100-mg tablet strengths in normal subjects","volume":"63","author":"Kaiko","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0440","article-title":"The pharmacokinetics of morphine from MST continus suspension","author":"Smith","year":"1997"},{"issue":"7","key":"10.1016\/bs.pmch.2019.01.001_bb0445","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/0885-3924(92)90019-E","article-title":"Pharmacokinetics of two novel rectal controlled-release morphine formulations","volume":"7","author":"Babul","year":"1992","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0450","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1365-2125.1996.32810.x","article-title":"Effect of food on the comparative pharmacokinetics of modified-release morphine tablet formulations: oramorph SR and MST continus","volume":"41","author":"Drake","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0455","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2165\/00044011-199612020-00004","article-title":"Kapanol\u2122 capsules : pellet formulation provides alternative methods of administration of sustained-release morphine sulfate","volume":"12","author":"Jones","year":"1996","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/bs.pmch.2019.01.001_bb0460","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/0975-8453.75054","article-title":"Novel technologies of oral controlled release drug delivery system","volume":"1","author":"Patel","year":"2010","journal-title":"Syst Rev Pharm"},{"issue":"9","key":"10.1016\/bs.pmch.2019.01.001_bb0465","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.mattod.2016.01.016","article-title":"Controlled-release of opiods for improved pain management","volume":"19","author":"Martin","year":"2016","journal-title":"Mater Today"},{"issue":"5698","key":"10.1016\/bs.pmch.2019.01.001_bb0470","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0475","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1021\/ja00083a066","article-title":"First total synthesis of taxol .1. Functionalization of the B-ring","volume":"116","author":"Holton","year":"1994","journal-title":"J Am Chem Soc"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0480","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1021\/ja00083a067","article-title":"First total synthesis of taxol .2. Completion of the C-ring and D-ring","volume":"116","author":"Holton","year":"1994","journal-title":"J Am Chem Soc"},{"issue":"6464","key":"10.1016\/bs.pmch.2019.01.001_bb0485","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/367630a0","article-title":"Total synthesis of taxol","volume":"367","author":"Nicolaou","year":"1994","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0490","series-title":"Anticancer agents from natural products","first-page":"89","article-title":"Taxol and its analogs","author":"DGI","year":"2005"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0495","author":"Case Study"},{"issue":"7","key":"10.1016\/bs.pmch.2019.01.001_bb0500","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/bs.pmch.2019.01.001_bb0505","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0510","article-title":"Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an iv study","volume":"90","author":"Szeben","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/bs.pmch.2019.01.001_bb0515","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","article-title":"Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer","volume":"83","author":"Holmes","year":"1991","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0520","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","article-title":"Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms","volume":"111","author":"McGuire","year":"1989","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2019.01.001_bb0525","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0378-5173(01)00986-3","article-title":"Paclitaxel and its formulations","volume":"235","author":"Singla","year":"2002","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0530","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejpb.2008.11.010","article-title":"Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect","volume":"71","author":"Maeda","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0535","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2019.01.001_bb0540","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","article-title":"Paclitaxel: what has been done and the challenges remain ahead","volume":"526","author":"Bernabeu","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0545","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","article-title":"The battle of \u201cnano\u201d paclitaxel","volume":"122","author":"Sofias","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"10.1016\/bs.pmch.2019.01.001_bb0550","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrd3254","article-title":"Cabazitaxel","volume":"9","author":"Galsky","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/bs.pmch.2019.01.001_bb0555","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","article-title":"State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines","volume":"187","author":"Dawidczyk","year":"2014","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/bs.pmch.2019.01.001_bb0560","first-page":"123","article-title":"Formulation and evaluation of transdermal patch containing amphotericin B","volume":"5","author":"Thejeswi","year":"2015","journal-title":"Int J Novel Trends Pharm Sci"},{"issue":"1\u20132","key":"10.1016\/bs.pmch.2019.01.001_bb0565","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jsbmb.2007.10.010","article-title":"Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men","volume":"109","author":"Raynaud","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/bs.pmch.2019.01.001_bb0570","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cpdd.431","article-title":"Pharmacokinetic evaluation of two nicotine patches in smokers","volume":"7","author":"Rasmussen","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/bs.pmch.2019.01.001_bb0575","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archfami.7.6.569","article-title":"Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation","volume":"7","author":"Davidson","year":"1998","journal-title":"Arch Fam Med"},{"issue":"21","key":"10.1016\/bs.pmch.2019.01.001_bb0580","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.2217\/nnm.15.155","article-title":"Lung cancer nanomedicine: potentials and pitfalls","volume":"10","author":"Bolukbas","year":"2015","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"10.1016\/bs.pmch.2019.01.001_bb0585","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jconrel.2013.09.026","article-title":"Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice","volume":"172","author":"Stirland","year":"2013","journal-title":"J Control Release"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646819300013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646819300013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T06:32:11Z","timestamp":1552545131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079646819300013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780444642776"],"references-count":116,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2019.01.001","relation":{},"ISSN":["0079-6468"],"issn-type":[{"value":"0079-6468","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}